The Southern Medical Journal (SMJ) is the official, peer-reviewed journal of the Southern Medical Association. It has a multidisciplinary and inter-professional focus that covers a broad range of topics relevant to physicians and other healthcare specialists.
SMJ // Article
Case Report
Metastatic Insulinoma: Case Report and Review of the Literature
Abstract
A 64-year-old nondiabetic woman presented with spells of lightheadedness and diaphoresis associated with lethargy and hunger of 2 weeks’ duration. Physical examination was unremarkable; however, her fasting plasma glucose was 66 mg/dl, with concurrent plasma insulin of 171 μIU/ml (normal, 5–27 μIU/ml). Her C-peptide and proinsulin levels were elevated, with negative insulin antibody and negative urinary sulfonylurea levels. Abdominal computed tomographic scan demonstrated a 5 × 4-cm mass in the tail of the pancreas and many liver metastases. She underwent resection of the pancreatic mass, radiofrequency ablation, and cauterization of hepatic lesions. Histology confirmed pancreatic insulinoma. Ten months later, she was free of hypoglycemic symptoms, with normal plasma insulin C-peptide and significantly decreased proinsulin levels. Insulinomas are rare, predominantly benign tumors. Surgery is the only curative treatment. Octreotide can be used to control hormone secretion and tumor growth. Other treatments include hepatic embolization, radiotherapy, chemotherapy, and liver transplantation.This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. Galbut DL, Markowitz AM. Insulinoma: Diagnosis, surgical management and long-term follow-up—Review of 41 cases. Am J Surg 1980; 139: 682–690.
2. Boukhman MP, Karam JH, Shaver J, et al. Insulinoma: Experience from 1950 to 1995. West J Med 1998; 169: 98–104.
3. Perry RR, Vinik AI. Clinical Review 72: Diagnosis and management of functioning islet cell tumors. J Clin Endocrinol Metab 1995; 80: 2273–2278.
4. Walters EG, Tavare JM, Denton RM, et al. Hypoglycaemia due to an insulin-receptor antibody in Hodgkin’s disease. Lancet 1987; 1: 241–243.
5. Boden G, Shimoyama R, Ray TK, et al. Effects of anti-insulin receptor antibodies on in vivo insulin metabolism. Diabetes 1985; 34: 342–346.
6. Taylor SI, Barbetti F, Accili D, et al. Syndromes of autoimmunity and hypoglycemia: Autoantibodies directed against insulin and its receptor. Endocrinol Metab Clin North Am 1989; 18: 123–143.
7. Delcore R, Friesen SR. Gastrointestinal neuroendocrine tumors. J Am Coll Surg 1994; 178: 187–211.
8. Service FJ, McMahon MM, O’Brien PC, et al. Functioning insulinoma: Incidence, recurrence, and long-term survival of patients—A 60-year study. Mayo Clin Proc 1991; 66: 711–719.
9. Kloppel G, Heitz PU. Pancreatic endocrine tumors. Pathol Res Pract 1988; 183: 155–168.
10. King AD, Ko GT, Yeung VT, et al. Dual phase spiral CT in the detection of small insulinomas of the pancreas. Br J Radiol 1998; 71: 20–23.
11. Lightdale CJ, Botet JF, Woodruff JM, et al. Localization of endocrine tumors of the pancreas with endoscopic ultrasonography. Cancer 1991; 68: 1815–1820.
12. Rosch T, Lightdale CJ, Botet JF, et al. Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med 1992; 326: 1721–1726.
13. Aoki T, Sakon M, Ohzato H, et al. Evaluation of preoperative and intraoperative arterial stimulation and venous sampling for diagnosis and surgical resection of insulinoma. Surgery 1999; 126: 968–973.
14. Owens LV, Huth JF, Cance WG. Insulinoma: Pitfalls in preoperative localization. Eur J Surg Oncol 1995; 21: 326–328.
15. Huai JC, Zhang W, Niu HO, et al. Localization and surgical treatment of pancreatic insulinomas guided by intraoperative ultrasound. Am J Surg 1998; 175: 18–21.
16. Schofl C, Borger J, Mader T, et al. Tolbutamide and diazoxide modulate phospholipase C-linked Ca2+ signaling and insulin secretion in β-cells. Am J Physiol Endocrinol Metab 2000; 278: E639–E647.
17. Shaer AJ. Management of hyperinsulinemia with diazoxide in an elderly hemodialysis patient. Nephron 2001; 89: 337–339.
18. Alberts AS, Falkson G. Rapid reversal of life-threatening hypoglycaemia with a somatostatin analogue (octreotide): A case report. S Afr Med J 1988; 74: 75–76.
19. Oda Y, Tanaka Y, Naruse T, et al. Expression of somatostatin receptor and effects of somatostatin analog on pancreatic endocrine tumors. Surg Today 2002; 32: 690–694.
20. De Jong M, Valkema R, Jamar F, et al. Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings. Semin Nucl Med 2002; 32: 133–140.
21. Nielsen MF, Dinneen S, Basu A, et al. Failure of nocturnal changes in growth hormone to alter carbohydrate tolerance the following morning. Diabetologia 1998; 41: 1064–1072.
22. Di Mauro M, Papalia G, Le Moli R, et al. Effect of octreotide on insulin requirement, hepatic glucose production, growth hormone, glucagon and c-peptide levels in type 2 diabetic patients with chronic renal failure or normal renal function. Diabetes Res Clin Pract 2001; 51: 45–50.
23. Brentjens R, Saltz L. Islet cell tumors of the pancreas: The medical oncologist’s perspective. Surg Clin North Am 2001; 81: 527–542.
24. Frank M, Klose KJ, Wied M, et al. Combination therapy with octreotide and α-interferon: Effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol 1999; 94: 1381–1387.
25. Saltz L, Kemeny N, Schwartz G, et al. A phase II trial of α-interferon and 5-fluorouracil in patients with advanced carcinoid and islet cell tumors. Cancer 1994; 74: 958–961.
